Trials soon ready
Clinical trials expected to report results within the next 6 months, ranked by how much the coming result could matter. Each trial shows its estimated finish date, explained in plain language.
This page shows companies working on cures and vaccines first, on purpose. We believe investor interest in cures leads to more cure trials. Why we do this.
Results due in the coming weeks
These trials are in their final phase, the companies running them are on the stock market, and results are due within weeks. A final-phase result is usually the last big test before a treatment can be approved, and it can move the company's value in either direction. We list them up top so you see the nearest dates first.
-
Gene therapy slows vision loss in stargardt disease trial Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
New hepatitis c pill aims to cut treatment time in half Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
New hope for chronic hives: barzolvolimab in Late-Stage trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
-
New pill could tame focal seizures when other drugs fail Results expected Oct 2026 (estimated) 🚀 Make-or-break
-
New eye drug could slash injection frequency for wet AMD patients Results expected Oct 2026 (estimated) 🚀 Make-or-break
The weekly investor briefing
One email every Sunday: which trial results are due in the coming weeks, what read out in the past week, and the small companies with a make-or-break result ahead. Free, and every issue has a one-click unsubscribe.
We'll send one confirmation email first — you're not subscribed until you click it.
-
Engineered immune cells target CD70 in kidney cancer
Cure OngoingThis is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
Results expected Dec 2026 (estimated)
Phase 1/2 • Sponsor: Adicet Therapeutics • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
Result impactVery highMicro-cap Phase 2 Readout in ~2 moA small company. This result carries real weight for it.
Adicet Bio · ACET NASDAQ Trade on eToro (ad)Why investors are watching
Adicet Bio runs this Phase 1/2 trial of ADI-270, an engineered gamma-delta CAR Vδ1 T cell therapy that targets CD70, in adults with relapsed or refractory clear cell renal cell carcinoma. The study tests dose escalation and dose expansion across 60 planned participants. For a micro-cap company, this readout carries the whole story: it is the main evidence that the platform works in patients.
If it works: A positive result could support further development of ADI-270 and draw partner or financing interest. It may also validate the company's engineered gamma-delta T cell approach beyond this one cancer.
If it fails: Early-phase trials often fail on safety, tolerability, or signs of benefit. A failure or delay could leave the company with limited clinical momentum and few other late-stage assets.
AI-written from the trial record. Speculative, and not investment advice.
-
Can a single eye injection restore sight in genetic blindness?
Cure OngoingThis is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects…
Results expected Mar 2027 (estimated)
Phase 1/2 • Sponsor: Ocugen • Aim: Cure
Last updated Aug 02, 2026 00:00 UTC
Result impactVery highMicro-cap Phase 2 Readout in ~5 moA small company. This result carries real weight for it.
Ocugen · OCGN NASDAQ Trade on eToro (ad)Why investors are watching
Ocugen is a micro-cap company, so this Phase 1/2 trial of OCU400, a gene therapy for three inherited retinal diseases, is a core value driver. The trial tests safety and efficacy in 22 to 24 patients, and a positive readout could validate the therapy's broad approach across multiple mutations. For a company this size, the result of this small study carries outsized weight.
If it works: A positive safety and efficacy result could position OCU400 as a promising treatment for multiple forms of blindness, potentially attracting partners or funding. It could also support the company's path toward larger trials and eventual regulatory discussions.
If it fails: The trial could fail to show meaningful vision improvement or reveal safety problems, which would likely set the program back. Early-stage trials often fail, and a negative result for a micro-cap company could be severe, as the company has few other assets to fall back on.
AI-written from the trial record. Speculative, and not investment advice.
-
New vaccine aims to better protect blood cancer patients from COVID-19
Vaccine OngoingThis phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-CM04S1 belongs to a category c…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: GeoVax, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 09:04 UTC
Result impactHighMicro-cap Phase 2 Readout in ~3 moA small company. This result carries real weight for it.
GeoVax, Inc. · GOVX NASDAQ Trade on eToro (ad)Why investors are watching
GeoVax is testing its vaccine GEO-CM04S1 against standard mRNA COVID-19 vaccines in 63 blood cancer patients who had stem cell transplants or cellular therapy. This is a small company, so this phase 2 readout could define whether its vaccine has a meaningful edge in a vulnerable patient group where standard vaccines may work poorly.
If it works: If GEO-CM04S1 produces a stronger immune response or better protection than mRNA vaccines in these patients, GeoVax could gain a foothold in a niche market for immunocompromised people. That result might also support further development and partnerships.
If it fails: The trial could fail to show an advantage, or the company could face delays in enrollment or data. Most phase 2 trials do not lead to approved products, so a negative or unclear result would likely hurt the company's prospects.
AI-written from the trial record. Speculative, and not investment advice.
-
RSV booster study aims to keep seniors safe for five seasons
Vaccine OngoingThe purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vac…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jul 31, 2026 00:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactHighLarge company Follow-on study Readout in ~1 wkA follow-on study — an extension, safety or dosing run, not the deciding result.
-
New pneumonia vaccine VAX-31 aims to boost protection in older adults
Vaccine OngoingThe study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
Results expected Mar 2027 (estimated)
Phase 3 • Sponsor: Vaxcyte, Inc. • Aim: Vaccine
Last updated Jul 02, 2026 00:00 UTC
Vaxcyte, Inc. · PCVX NASDAQ Trade on eToro (ad)Result impactHighMid-cap Phase 3, decisive Readout in ~5 moA mid-sized company with other programmes alongside this one.
-
Pfizer gives lyme vaccine a fifth dose — will it boost protection?
Vaccine Recruiting nowThe purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactHighLarge company Phase 3, decisive Readout in ~2 moA large company. One readout moves the needle only so far.
-
New chickenpox shot shows promise in toddler trial
Vaccine Recruiting nowThe purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to healthy children. 3 months after first dose at 12 t…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 13:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~3 moA large company. One readout moves the needle only so far.
-
Major RSV vaccine trial for seniors nears completion
Vaccine OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New mRNA vaccine aims to stop the stomach flu
Vaccine OngoingThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Results expected Feb 2027 (estimated)
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:33 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~5 moA large company. One readout moves the needle only so far.
-
New vaccine aims to protect kids from pneumonia – study underway
Vaccine OngoingThe purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Vaccine
Last updated Jun 27, 2026 07:53 UTC
Sanofi S.A. · SNY NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~2 moA large company. One readout moves the needle only so far.
-
New mRNA shot targets bird flu: 4,000 volunteers needed
Vaccine OngoingThe purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 13, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New RSV vaccine aims to shield adults from severe respiratory infection
Vaccine Recruiting nowThe purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Aug 16, 2026 00:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New vaccine aims to shield sickle cell kids from deadly infections
Vaccine Recruiting nowThe purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Sanofi • Aim: Vaccine
Last updated Jun 27, 2026 12:08 UTC
Sanofi · SNY NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New RSV vaccine candidate aims to shield older adults from severe lung infections
Vaccine OngoingThis Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: AstraZeneca • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 2 Readout in ~2 wkA large company. One readout moves the needle only so far.
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
Cure OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: Arcellx, Inc. • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Result impactModerateLarge company Follow-on study Readout in ~1 wkA follow-on study — an extension, safety or dosing run, not the deciding result.
-
Two-Drug malaria punch targets faster cure in kids
Cure Recruiting nowThis was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
Results expected Feb 2027 (estimated)
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
Novartis AG · NVS NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 2 Readout in ~5 moA large company. One readout moves the needle only so far.
Why cures and vaccines come first here
We built this site so people can find trials that might cure them. These investor pages work toward the same goal from the money side: they show companies working on cures and vaccines first, and we promote those companies on purpose. We believe investor interest in cures and vaccines means more money for the companies chasing them, and more cure and vaccine trials as a result.
Nothing is hidden by this. Every trial soon ready, whatever its aim, is on the full list . Rankings are computed from the public trial record and the company's size. No company can pay to be listed or ranked higher.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. We think this page is more useful when you can go straight to somewhere that sells the stock, so the "Listed companies" view shows only companies our broker partner carries; switch to all sponsors for the unfiltered list. Ranking is never for sale: no company can pay to appear here or to place higher.